Abstract

IntroductionUrinary nicotine and cotinine levels are often measured as biomarkers for tobacco smoke exposure. However, these biomarkers are not appropriate to evaluate the effects of quitting smoking for several days, because of their short half-lives. In this study, we focused on the changes in the urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) levels of 55 patients in a smoking cessation program, because of the long half-life. At the same time, urinary 7-methylguanine (m7Gua) and 8-hydroxy-2′-deoxyguanosine (8-OHdG), as DNA damage markers of cigarette smoking, were also measured.ResultsIn the subjects who completed the quit-smoking program (18 subjects out of 55), the urinary nicotine and cotinine levels decreased to 1.7 and 0.2% at 8 weeks after the first visit to the clinic. By contrast, the NNAL levels decreased to 12.3% at 8 weeks after quitting smoking. During the same period, the urinary m7Gua levels significantly decreased, from 27.32 μg/mg creatinine to 14.17 μg/mg creatinine by the elimination of subjects who showed increased levels of NNAL during the smoking cessation program. The 8-OHdG levels were also reduced within the same period, but were not significantly different. From the all data analysis, the urinary levels of cotinine and NNAL positively correlated with the level of m7Gua.ConclusionsNNAL may be an appropriate exposure marker for evaluating the smoking status of patients in a smoking cessation program. The urinary cotinine and NNAL levels positively correlated with the m7Gua levels.

Highlights

  • Urinary nicotine and cotinine levels are often measured as biomarkers for tobacco smoke exposure

  • The urinary cotinine and NNAL levels positively correlated with the m7Gua levels

  • The purpose of this study is to investigate the reductions of cigarette smoking exposure markers and DNA damage markers (m7Gua and 8-OHdG) in patients participating in a smoking cessation program

Read more

Summary

Introduction

Urinary nicotine and cotinine levels are often measured as biomarkers for tobacco smoke exposure. These biomarkers are not appropriate to evaluate the effects of quitting smoking for several days, because of their short half-lives. We focused on the changes in the urinary 4-(methylnitrosamino)-1-(3-pyridyl)1-butanol (NNAL) levels of 55 patients in a smoking cessation program, because of the long half-life. NNAL is a tobacco-specific nitrosamine and a metabolite of the carcinogenic 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in humans [3]. As urine contains quantitatively significant NNK metabolites, the NNAL levels in urine are critically useful in studies of human exposure to tobacco smoke. Only a few studies have used urinary NNAL as an indicator of smoking cessation in clinical settings

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call